Evaluation of Root Coverage After the Use of Coronally Advanced Flap Either With Advanced Paltelet Rich Fibrin or Subepithilial Connective Tissue Graft in Treatment of Miller Class I and II Gingival Recession.
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | October 1, 2018 | ||
First Posted Date ICMJE | October 4, 2018 | ||
Last Update Posted Date | October 5, 2018 | ||
Actual Study Start Date ICMJE | October 2018 | ||
Estimated Primary Completion Date | July 2019 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
root coverage[ Time Frame: 9 months ] measured in millimeter |
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Current Secondary Outcome Measures ICMJE |
|
||
Descriptive Information | |||
Brief Title ICMJE | Evaluation of Root Coverage After the Use of Coronally Advanced Flap Either With Advanced Paltelet Rich Fibrin or Subepithilial Connective Tissue Graft in Treatment of Miller Class I and II Gingival Recession. |
||
Official Title ICMJE | Root Coverage After the Use of Coronally Advanced Flap With Advanced Platelet Rich Fibrin (A- PRF) Compared With Subepithelial Connective Tissue Graft in Management of Miller Class I and II Gingival Recession. A Randomized Clinical Trial |
||
Brief Summary | patients with Miller class I , II gingival recession will be divided into 2 groups (control, intervention).the control one will receive coronally advanced flap with subepithililal connective tissue graft harvested from the palate while the intervention one will have coronally advanced flap with advanced platelet rich fibrin(A-PRF).as it represent a new generation of platelet concentrate allow for better healing and root coverage results. Null hypothesis: In patients with Miller class I and II gingival recession, there is no difference in amount of root coverage (mm) following the application of SCTG+A-PRF compared to CAF+SCTG. |
||
Detailed Description | - Population (P): Patients with single Miller class I, II gingival recessions. - Intervention (I): Coronally advanced flap (CAF) plus platelet rich fibrin (A-PRF). - Comparator (C): Coronally advanced flap (CAF) plus subepithelial connective tissue graft (SCTG). - Primary Outcome (O): Root coverage (mm). - Time frame: 9 months. - Study design: Randomized controlled clinical trial. - Patients are to be selected from the outpatient clinic of the department of Oral Medicine and Periodontology-Cairo University | ||
Study Type ICMJE | Interventional | ||
Study Phase | N/A | ||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Masking: Interventional Masking Description: Primary Purpose: Treatment |
||
Condition ICMJE | |||
Intervention ICMJE |
|
||
Study Arms |
|
||
Recruitment Information | |||
Recruitment Status ICMJE | Not yet recruiting | ||
Estimated Enrollment ICMJE |
20 | ||
Original Estimated Enrollment ICMJE | Same as current | ||
Estimated Study Completion Date | October 2019 | ||
Estimated Primary Completion Date | July 2019 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria: - Systemically healthy patients 18 years old and older both males and females. - Good oral hygiene after phase I therapy. - Miller's class I or II gingival recession. - Not using antibiotics, steroids, chemotherapy or other medications that may modify results of the surgery and healing. - Cooperative patients able and accept to come for follow up appointments Exclusion Criteria: - Pregnant or lactating females. - Current Smokers. - Patients with any systemic disease that may affect the periodontal healing. - Teeth with endodontic treatment, buccal restoration or caries. - Patients with poor oral hygiene | ||
Sex/Gender |
|
||
Ages | 15 Years and older (Adult, Older Adult) | ||
Accepts Healthy Volunteers | No | ||
Listed Location Countries ICMJE | |||
Removed Location Countries | |||
Administrative Information | Has Data Monitoring Committee | Yes | |
U.S. FDA-regulated Product |
Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No |
||
IPD Sharing Statement |
|
||
Responsible Party | heba samir,Cairo University | ||
Study Sponsor ICMJE | Cairo University | ||
Collaborators ICMJE | |||
Investigators ICMJE |
|
||
PRS Account | Cairo University | ||
Verification Date | October 2018 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |